TNFRSF17 and plasma cell myeloma: Currently, there are four approved CAR-T cell products directed to CD19 (CART-19) for B cell malignancies (axi-cel, tisa-cel, liso-cel, and brexu-cel) and two products targeting B-cell maturation antigen (BCMA) (CART-BCMA) (ide-cel and cilta-cel) for multiple myeloma (MM) patients (1, 2).